|Bid||325.48 x 900|
|Ask||325.74 x 1100|
|Day's range||322.18 - 327.33|
|52-week range||226.05 - 341.70|
|Beta (5Y monthly)||0.38|
|PE ratio (TTM)||51.89|
|Forward dividend & yield||3.92 (1.22%)|
|Ex-dividend date||12 Aug 2022|
|1y target est||N/A|
Eli Lilly (LLY) closed the most recent trading day at $321.55, moving -0.56% from the previous trading session.
Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%. The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab. Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.
Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.